Compounded GLP-1 Formulation
Compounded GLP-1 receptor agonist, with cyanocobalamin or glycine
- Format
- Injectable
- Spec
- B12 or glycine co-formulation, multiple concentrations
- Sourcing
- FDA-registered 503A pharmacy
Specifications
Available Formulations
Compounded to order by our 503A pharmacy partner. This lists what can be prepared, and is not a dosing recommendation.
| Strength & size | Beyond-use date | Quantity per fill |
|---|---|---|
| 0.6 mg-500 mcg/mL (2 mL) (1.2 mg vial)B12 | 90 days | Max 2 vials |
| 1.2 mg-500 mcg/mL (2 mL) (2.4 mg vial)B12 | 90 days | Max 2 vials |
| 2.2 mg-500 mcg/mL (2 mL) (4.4 mg vial)B12 | 90 days | Max 2 vials |
| 3.4 mg-500 mcg/mL (2 mL) (6.8 mg vial)B12 | 90 days | Max 2 vials |
| 4.1 mg-500 mcg/mL (2 mL) (8.2 mg vial)B12 | 90 days | Max 2 vials |
| 5.6 mg-500 mcg/mL (2 mL) (11.2 mg vial)B12 | 90 days | Max 2 vials |
| 2.5 mg-500 mcg/mL (5 mL) (12.5 mg vial)B12 | 90 days | Max 2 vials |
| 5 mg-500 mcg/mL (3 mL) (15 mg vial)B12 | 90 days | Max 2 vials |
| 5 mg-500 mcg/mL (4 mL) (20 mg vial)B12 | 90 days | Max 2 vials |
| 10 mg-500 mcg/mL (3 mL) (30 mg vial)B12 | 90 days | Max 2 vials |
| 5 mg-2.5 mg/mL (2 mL) (10 mg vial)Glycine | 90 days | Max 2 vials |
| 5 mg-2.5 mg/mL (6 mL) (30 mg vial)Glycine | 90 days | Max 2 vials |
- Sterility
- Endotoxin and sterility tested per sterile batch
- Compounding standard
- USP <797> and <800>
- Pricing
- Available on verified account approval
Beyond-use dates are assigned at compounding per USP <795> and <797> and printed on each container label. Values here are a planning reference and may vary by formulation, container and storage. The shortest applicable limit always governs: assigned beyond-use date, product stability, in-use and puncture dating, prescribed directions, and pharmacist review.
Research Summary
Mechanism & Physiological Role
GLP-1 receptor agonists activate incretin signaling to promote glucose-dependent insulin secretion, delay gastric emptying, and reduce appetite via central pathways.
Clinical & Research Applications
Discussed in the peer-reviewed literature in the context of weight management and metabolic-syndrome research. 503A compounded formulations are prepared per individual patient prescriptions.
Scientific Publications
Peer-Reviewed References
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding JPH, Batterham RL, Calanna S, et al.
New England Journal of Medicine · 2021 · PMID: 33567185
All compounded formulations are prepared by a licensed 503A sterile compounding pharmacy partner. Compounds are available to NPI-verified licensed practitioners only, per individual patient prescriptions in accordance with applicable state and federal law. Compounded medications are not FDA-approved. Pricing available upon verified account approval.
Ready to add Compounded GLP-1 Formulation to your protocol?
Compounded formulations are dispensed by our 503A pharmacy partner, licensed by the Texas State Board of Pharmacy, under a valid patient-specific prescription. Prefer a formal quote? Request formulation-specific pricing instead.